Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MREO 
Mereo BioPharma Group PLC ADR (MREO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MREO (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 3.55% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 630.80M USD | Price to earnings Ratio - | 1Y Target Price 7.22 |
Price to earnings Ratio - | 1Y Target Price 7.22 | ||
Volume (30-day avg) 1422551 | Beta 0.97 | 52 Weeks Range 2.11 - 5.02 | Updated Date 04/1/2025 |
52 Weeks Range 2.11 - 5.02 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.25 |
Earnings Date
Report Date 2025-03-26 | When - | Estimate - | Actual -0.045 |
Profitability
Profit Margin - | Operating Margin (TTM) -3790.4% |
Management Effectiveness
Return on Assets (TTM) -23.86% | Return on Equity (TTM) -48.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 281657625 | Price to Sales(TTM) 598.13 |
Enterprise Value 281657625 | Price to Sales(TTM) 598.13 | ||
Enterprise Value to Revenue 576.45 | Enterprise Value to EBITDA -1.21 | Shares Outstanding 153852992 | Shares Floating 485069441 |
Shares Outstanding 153852992 | Shares Floating 485069441 | ||
Percent Insiders 1.03 | Percent Institutions 65.67 |
Analyst Ratings
Rating 4.86 | Target Price 7.22 | Buy 1 | Strong Buy 6 |
Buy 1 | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Mereo BioPharma Group PLC ADR
Company Overview
History and Background
Mereo BioPharma Group PLC ADR, founded in 2015, is a biopharmaceutical company focused on rare diseases and oncology. It has pursued a strategy of acquiring and developing clinical-stage assets from larger pharmaceutical companies.
Core Business Areas
- Oncology: Development of cancer therapies targeting specific tumor microenvironments.
- Rare Diseases: Development of treatments for rare genetic and inflammatory conditions.
Leadership and Structure
Dr. Denise Scots-Knight is the CEO. The company operates with a board of directors overseeing strategic direction. The structure includes research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Setrusumab: Setrusumab is being developed for osteogenesis imperfecta (OI). The company has not yet reported revenue from this product since it is still in clinical trials. Competitors include gene therapies and bisphosphonates for managing OI symptoms. Market share is currently 0 as Setrusumab is not approved.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and significant market competition. Focus is growing on rare diseases and personalized medicine.
Positioning
Mereo BioPharma is positioned as a company specializing in acquiring and developing promising assets in niche therapeutic areas. Its competitive advantage lies in its ability to identify and advance undervalued assets.
Total Addressable Market (TAM)
The TAM for rare diseases is significant and growing. Setrusumab is targetting OI. Mereo is positioned to capture a share of this growing market, potentially reaching several billion USD. It is a new approach for OI.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Diverse pipeline of clinical-stage assets
- Focus on rare diseases with high unmet need
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Dependence on partnerships for commercialization
Opportunities
- Potential for accelerated regulatory approval pathways
- Increasing investor interest in rare disease therapies
- Strategic partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established players
Competitors and Market Share
Key Competitors
- LLY
- NVS
- BMRN
Competitive Landscape
Mereo BioPharma competes with larger, more established pharmaceutical companies. Its advantage lies in its focused approach and potentially innovative therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by pipeline advancement and partnership deals rather than revenue.
Future Projections: Future growth is contingent on successful clinical trials and potential commercialization or out-licensing of its assets. Analyst estimates vary based on trial outcomes.
Recent Initiatives: Recent initiatives include advancing Setrusumab in OI and exploring additional therapeutic areas.
Summary
Mereo BioPharma is a clinical-stage biopharmaceutical company focused on rare diseases and oncology. The company is still early in its lifecycle with the success being dependent on clinical trials. Mereo is a higher-risk, higher-reward investment, as their ability to successfully bring drugs to market will be critical for their continued success. The focus on niche therapeutics and innovative approach may allow for rapid growth.
Similar Companies
BMRN
Biomarin Pharmaceutical Inc
BMRN
Biomarin Pharmaceutical Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
NVS
Novartis AG ADR
NVS
Novartis AG ADR
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mereo BioPharma Group PLC ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-04-24 | Co-Founder, CEO & Executive Director Dr. Denise Vera Scots-Knight Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 36 | Website https://www.mereobiopharma.com |
Full time employees 36 | Website https://www.mereobiopharma.com | ||
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.